• Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies

  • Jul 24 2024
  • Length: 38 mins
  • Podcast

Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies By cover art

Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies

Listen for free

View show details

  • Summary

  • touchIN CONVERSATION for touchONCOLOGY

    Listen to a medical oncologist and a pathologist as they discuss HER2 alterations in non-small cell lung cancer (NSCLC), including the different types of HER2 alterations, key considerations for HER2 testing and the latest data for HER2-targeting treatments.

    The experts

    • Prof. Enriqueta Felip - Medical Oncologist, Vall d'Hebron University Hospital, Barcelona, Spain
    • Prof. Keith Kerr - Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen, UK

    This touchPODCAST is for HCPs outside of the UK only.

    This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

    For further information visit our website:

    https://touchoncologyime.org/her2_nsclc_testing_and_targeted_therapies/
    Show more Show less
activate_primeday_promo_in_buybox_DT
Science
Show more Show less

What listeners say about Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available